Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00712920 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies
A Phase 3 study, sponsored by Meda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 581
- Enrollment target
NCT00712920: Completed Phase 3 study, sponsored by Meda Pharmaceuticals.
NCT00712920 is a Phase 3 study that has completed, run by Meda Pharmaceuticals. The registered enrollment target is 581 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00712920, a Phase 3 study, has completed, sponsored by Meda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 581 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if two allergy medications are more effective than placebo.
Primary Outcome
Reflective total nasal symptom score consisting of Runny nose, itchy nose, nasal Congestion, and Sneezing was assessed twice daily. Each symptom is rated on a scale from 0-3: 0=none, 1=mild, 2=moderate, and 3=severe. Total possible score is 24 per day Least square means (LS Mean) was controlled for study day as the within-patient effect, treatment group and site as the between-patient effects, treatment by-study day interaction, and basline as a covariate.
Interventions
- DRUG Placebo
- DRUG 0.15% azelastine hydrochloride
- DRUG 0.1% azelastine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 581 participants |
| Start Date | 2007-01 |
| Phase | Phase 3 |
What the finished NCT00712920 record still lists
NCT00712920 is an interventional study that assigns participants to a tested intervention. The registered 581 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (25% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00712920 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00712920 about?
NCT00712920 is a clinical study titled "A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies". The purpose of this study is to determine if two allergy medications are more effective than placebo.
What is the current status of trial NCT00712920?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 581 participants. The study started on 2007-01.
What interventions are being tested in trial NCT00712920?
The interventions under investigation include: Placebo (DRUG), 0.15% azelastine hydrochloride (DRUG), 0.1% azelastine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00712920?
This trial is sponsored by Meda Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00712920's enrollment target sits among peer trials
581 656th of 2000 higher than 1,345 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06350097 · 582 participants · Phase 3
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- NCT06563895 · 582 participants · Phase 3
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- NCT06819007 · 582 participants · Phase 3
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- NCT04575935 · 580 participants · Phase 3
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia